

ASX Release  
15<sup>th</sup> October 2025

## EARLY FDA APPROVAL – \$2.15 MILLION PLACEMENT TO ACCELERATE SOMFIT D COMMERCIALISATION

### *Somfit D Pipeline Now Exceeds US\$20 Million*

Compumedics Limited (ASX: CMP) (“Compumedics” or “the Company”), a leading global medical technology company in sleep diagnostics, brain imaging and neuro-monitoring, is pleased to advise it has successfully completed a Placement to raise \$2.15 million (before costs) at \$0.285 per share. The Placement is supported by existing, new institutional and sophisticated investors.

The Placement follows continued sales momentum evident across the Group, driven by accelerating Somfit® adoption in the United States, progress in OrionMEG® commercialisation, and strengthening order flows in Europe and Asia.

### **BUSINESS UPDATE – ENTERING COMMERCIAL SCALE**

Compumedics is entering its most significant commercial expansion phase, underpinned by three strategic growth pillars:

- **Somfit® – Scaling US Home Sleep Market**

Early FDA approval of Somfit D, combined with a Somfit pipeline now exceeding US\$20 million, positions CMP at the forefront of the rapidly expanding US home sleep testing (HST) market, estimated at ~US\$250 million annually and growing at up to 25% p.a.. With partnerships across IDTFs, pharmacies, and major CPAP players, Somfit® has moved beyond pilots and into commercial rollout

- **OrionMEG® – Global Neuroscience Expansion**

OrionMEG® is Compumedics’ breakthrough in functional brain imaging, independently validated by UCSD as a world-leading MEG platform. With ~\$15 million in FY26 orders and over \$20 million in early demand from China, it is now targeting U.S. entry. Its greater temporal resolution is most suited to enormous health burden neuro-functional disorders such as epilepsy, autism, Alzheimer’s, Parkinsons, traumatic brain injury, and mental disorders. With MRI-like adoption potential in a ~\$13.6 billion market, OrionMEG® has the potential to become a transformative global platform alongside Compumedics’ sleep diagnostics leadership.

For personal use only

**• SaaS-Driven Margin Expansion**

Over 770,000 studies have been completed through CMP's sleep and neurology SaaS platforms (Nexus 360®), generating high recurring revenue, improved gross margins, and expanding lifetime customer value

With FY26 execution underway, strengthened US sales leadership and ongoing Board renewal, CMP is positioned to deliver not only operational performance but a structural valuation re-rating against peers.

**USE OF PLACEMENT PROCEEDS**

**Somfit D Commercial Scale-Up**

Acceleration of Somfit D manufacturing and tooling, following early FDA approval (three months ahead of schedule), to support the US\$20 million Somfit D pipeline in the United States. Funds will be applied to fast-tracking production and working capital ahead of expected 2H FY26 revenue.

**OrionMEG® Capacity Expansion**

Increase in in-house and partner manufacturing capacity to support delivery of contracted MEG systems into China, and to prepare for anticipated sales into the US and EU markets. This ensures CMP can meet growing global demand for its world-leading brain imaging platform.

**Working Capital & Commercial Deployment**

General working capital to support logistics, customer onboarding and commercial execution across the US, Europe and Asia as CMP transitions from pilot adoption to full-scale rollout of Somfit® and OrionMEG®.

**Capital Raising Details**

<b>Details</b>	<b>Placement</b>
Amount Raised	\$2.150 million (before costs)
Offer Price	\$0.285 per share
Shares to be Issued	7,543,860 new shares
Placement Structure	Within LR7.1 capacity

The Placement was completed at a 3% discount to the 15-day VWAP of \$0.295 and a 16% discount to the last traded price of \$0.34.

Each Share issued under the Capital Raising will rank equally with existing Shares from the date of issue.

PAC Partners Securities Pty Ltd (**PAC Partners**) acted as Lead Manager to the Placement and will be paid a 6% capital raising fee.

For personal use only

## **FY26 GUIDANCE REAFFIRMED**

Compumedics reaffirms FY26 guidance:

- **Revenue: > \$70 million**
- **EBITDA: ~ \$9 million**

### **Dr. David Burton, Executive Chairman and CEO, said:**

*“The early FDA clearance of Somfit D, combined with a US\$20 million pipeline, marks the beginning of Somfit’s commercial scale-up. This capital allows us to ramp up manufacturing capacity, meet demand, and accelerate onboarding of major US sleep operators and pharmacy partners. Somfit D is no longer in trials, it is moving into revenue.”*

### **About Compumedics Limited**

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

### **For further information, please contact:**

**Dr. David Burton**  
**Executive Chairman, CEO**

**P: +61 3 8420 7300**

**F: +61 3 8420 7399**

**David Lawson**  
**Director, CFO**

**P: + 61 3 8420 7300**

**F: +61 3 8420 7399**

**Authorised for lodgement by Compumedics Limited’s Board of Directors**